Insights

1. Executive Summary: The Cost of Strategic Blindness In the pharmaceutical sector, the difference between a franchise that generates billions […]

1. Executive Summary Pharmaceutical patent thickets, dense and overlapping webs of intellectual property rights, have become a formidable barrier to

The traditional path of de novo drug discovery is often described as a grueling marathon, a journey characterized by astronomical

1. The Economic Imperative of Delay The pharmaceutical industry operates on a singular, brutal economic premise: the finite nature of

1. The Asset Management View of Litigation In the pharmaceutical industry, the expiration of a primary patent is not merely

The Imperative for an Evolved Generic Strategy: A New Paradigm of Value In the intricate ecosystem of modern healthcare, the

Introduction: The High-Stakes Battlefield of Generic Drug Market Entry For a pharmaceutical company, the journey to market is a strategic

Executive Summary The global pharmaceutical market presents two primary avenues for investors seeking to capitalize on the expiration of brand-name

The New Mandate: Understanding China’s IP Transformation For years, the narrative surrounding intellectual property in China has been one of